Theranostics Market - Global Forecast 2025-2032

The theranostics market is at the leading edge of precision medicine, integrating advanced diagnostics with targeted therapeutics to support data-driven healthcare decisions and improve patient care outcomes. Increasing demand for individualized treatment and ongoing investment in innovation fuel sector growth, with strategic implications for stakeholders worldwide.

Theranostics Market Snapshot

The Theranostics Market grew from USD 2.93 billion in 2024 to USD 3.32 billion in 2025 and is projected to reach USD 8.40 billion by 2032 at a CAGR of 14.07%.

Scope & Segmentation

• Product Types: Diagnostic Agents, Therapeutic Agents
• Technologies: Biomarker-Based Theranostics, Companion Diagnostics (CDx), Gene Therapy-Based Theranostics, Molecular Imaging, Nanotechnology-Based Theranostics, Radiopharmaceutical-Based Theranostics, Targeted Drug Delivery
• Application Areas: Autoimmune Disorders, Cardiovascular Diseases, Infectious Diseases, Inflammatory Diseases, Metabolic Disorders, Neurological Disorders, Oncology (Breast Cancer, Lung Cancer, Neuroendocrine Tumors, Prostate Cancer, Thyroid Cancer)
• End Users: Diagnostic Imaging Centers, Hospitals & Cancer Care Centers, Research & Academic Institutes, Specialty Clinics
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)

Competitive analysis covers Actinium Pharmaceuticals, Ariceum Therapeutics, Astellas Pharma, BAMF Health, Bayer AG, bioMérieux, Biosynth, Cardinal Health, Cerebral Therapeutics, Clarity Pharmaceuticals, Curasight, Curium, Evergreen Theragnostics, GE HealthCare Technologies, Hermes Medical Solutions, Icon Group, Indi Molecular, Integrated Clinical Oncology Network, Radiopharm Theranostics, Ratio Therapeutics, Siemens Healthineers, SOFIE Co., and Telix Pharmaceuticals.

Key Takeaways for Senior Decision Makers

• Market growth is closely tied to technological advances in molecular imaging, gene therapy, and radiopharmaceuticals, which streamline the transition from diagnosis to therapy and reduce systemic toxicity.
• Increasing collaboration between pharmaceutical firms, diagnostic companies, and research organizations expedites product development and supports shared innovation, allowing for stronger market positioning.
• Regulators are adapting approval pathways for integrated diagnostic-therapeutic products, empowering more rapid commercialization and reducing barriers for novel market entrants.
• Personalized medicine trends drive investment in digital health tools that facilitate remote patient monitoring and real-time therapy adjustment, aligning clinical results with individual needs and treatment objectives.
• Growth corridors are shaped by regional differences in regulatory environments, infrastructure readiness, and healthcare investment, requiring tailored entry and expansion strategies for each market.
• Flexible manufacturing strategies, including onshore production and modular facility design, will optimize supply chain resilience amid evolving tariff and trade policy pressures.

Tariff Impact on Supply Chains and Investments

New tariff measures in the United States have increased costs for critical components, affecting procurement and encouraging companies to reconsider sourcing and domestic manufacturing. These changes promote capacity building and innovation but can challenge emerging players due to rising capital requirements. Stakeholders are forming collaborative procurement networks and sharing research protocols to manage costs and maintain project momentum under tighter budgets.

Primary Keyword: Theranostics Market

Methodology & Data Sources

This report is based on a rigorous research framework, integrating secondary intelligence from peer-reviewed publications and industry reports with primary insights gathered via executive interviews. Findings were validated through data triangulation and iterative expert reviews to ensure reliability, objectivity, and actionable value for decision makers.

Why This Report Matters

• Gain a comprehensive view of technology and market trends relevant to clinical, manufacturing, and investment decisions.
• Assess regulatory and supply chain risks while identifying strategic partnership and expansion opportunities in high-potential regions.

This analysis provides executives with focused insights to drive operational efficiency and long-term competitive advantage by aligning offerings with evolving healthcare needs.

Conclusion

The theranostics market continues to evolve rapidly, reshaping global healthcare delivery. Senior leaders who embrace technology adoption, regulatory engagement, and cross-sector partnerships will position their organizations for sustainable growth within this high-impact domain.